Phase 3 Topline Results ‘Disappointing’ for Novel Antidepressant

In topline results from the phase 3 RELIANCE III trial, a novel NMDAR antagonist was no better than placebo as monotherapy for major depression ― despite showing earlier promise as add-on therapy.
Medscape Medical News
In topline results from the phase 3 RELIANCE III trial, a novel NMDAR antagonist was no better than placebo as monotherapy for major depression ― despite showing earlier promise as add-on therapy.
Medscape Medical News